John Baldoni, Phd

John Baldoni has over 40 years of experience in the pharmaceutical industry, including 29 years at GSK R&D with 11 of those years on its executive leadership team. He has participated in the research and development of scores of commercial products.

John’s most recent roles included SVP of GSK’s science and technology platforms and SVP of a small in silico GSK drug discovery unit. Baldoni has held other various positions at GSK including Senior Vice President, Preclinical Development; Vice President, Product Development; Director, Product Development; and Assistant Director, Biopharmaceutical Formulation Development, among others.

After leaving GSK in 2019, he spent a year at a stealth biotech. John is a proponent of seeking, integrating and implementing innovative approaches to drug discovery and development. He led several GSK innovation initiatives through internal teams, technology acquisitions and partnerships.

John conceptualized and is currently senior science advisor to the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium – an open membership, public/private partnership currently comprised of Pharma, Tech, Lawrence Livermore National Laboratory, Frederick National Laboratory for Cancer Research, and the University of California, San Francisco. John was also Chair of the Executive Committee of the Alliance for Artificial Intelligence in Healthcare, an organization formed to foster improved healthcare by responsible investment, invention and innovation in artificial intelligence.

John received his Ph.D. from Penn State University in biological chemistry.